GRANDE ALICIA 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Mar 30, 2023
Insider Transaction Report
Form 4
GRANDE ALICIA
Chief Accounting Officer
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2023-03-28$0.79/sh+58,216$45,991→ 108,773 total - Sale
Common stock, par value $0.001 per share
2023-03-28$16.55/sh−10,000$165,500→ 70,557 total - Sale
Common stock, par value $0.001 per share
2023-03-29$16.70/sh−20,000$334,000→ 60,557 total - Sale
Common stock, par value $0.001 per share
2023-03-29$16.67/sh−10,000$166,700→ 50,557 total - Exercise/Conversion
Options to purchase common stock
2023-03-28−58,216→ 1,345,834 totalExercise: $0.79Exp: 2023-06-15→ Common Stock (58,216 underlying) - Exercise/Conversion
Options to purchase common stock
2023-03-29−50,000→ 1,295,834 totalExercise: $1.13Exp: 2024-01-03→ Common Stock (50,000 underlying) - Sale
Common stock, par value $0.001 per share
2023-03-28$16.60/sh−28,216$468,386→ 80,557 total - Sale
Common stock, par value $0.001 per share
2023-03-28$16.52/sh−10,000$165,200→ 60,557 total - Sale
Common stock, par value $0.001 per share
2023-03-28$16.37/sh−10,000$163,700→ 50,557 total - Exercise/Conversion
Common stock, par value $0.001 per share
2023-03-29$1.13/sh+50,000$56,500→ 100,557 total - Sale
Common stock, par value $0.001 per share
2023-03-29$16.72/sh−20,000$334,400→ 80,557 total
Footnotes (3)
- [F1]Shares were sold to cover exercise price of options, tax withholding requirements and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Ms. Grande remains an officer of the Company.
- [F2]Options vested in two annual tranches beginning on June 15, 2017.
- [F3]Options vested in three annual tranches beginning on January 3, 2018.